Author:
Rabey Jose M.,Stryjer Rafael O.
Reference13 articles.
1. Birkmayer W, Riederer P, Ambrozi L, et al. Implications of combined treatment with “Madopar” and L- deprenyl in Parkinson’s disease. Lancet 1977;1:439–43.
2. Lees AJ, Shaw KM, Kohout LT, et al. Deprenyl in Parkinson’s disease. Lancet 1997;2:791–5.
3. Streifler M, Vardi J, Borenstein N, et al. S. B-type Monoamine oxidase (M.A.O.) inhibitors in long-term levodopa treated Parkinsonism. A combined clinical trial with L-deprenyl. Curr Ther Res Clin Exp 1980;27:643–8.
4. Lees AJ, on behalf of the Parkinsonian’s Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. BMJ 1995;311:1602–7.
5. Olanow CW, Myllyla VV, Sotaniemi KA, et al. Effects of selegiline on mortality in patients with Parkinson’s disease: a meta-analysis. Neurology 1998;51:825–30.